Acadian Asset Management
MLYS icon

Acadian Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

Acadian Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,908
Closed -$104K – 2171
2025
Q4 		$104K Buy
+2,908
New +$117K ﹤0.01% 1670
2024
Q4 		– Sell
-1,472
Closed -$17K – 1965
2024
Q3 		$17K Buy
+1,472
New +$17.8K ﹤0.01% 2000

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Acadian Asset Management's MLYS Position: Q1 2026 in Review

Acadian Asset Management sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 2,908 shares — an estimated $104K sold.

Acadian Asset Management first reported a position in MLYS in Q3 2024 and held it in 2 quarters. The position peaked at $104K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Acadian Asset Management reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 2,908 Mineralys Therapeutics shares in Q1 2026, an estimated $104K.
  • Acadian Asset Management first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 2 quarters.
  • Acadian Asset Management's Mineralys Therapeutics position peaked at $104K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.